

PLOS ONE

Psychometric evaluation of a quality of recovery score for the postanesthesia care unit – a prospective validation study --Manuscript Draft--

Manuscript Number:	PONE-D-22-18272
Article Type:	Research Article
Full Title:	Psychometric evaluation of a quality of recovery score for the postanesthesia care unit – a prospective validation study
Short Title:	Development of a quality of recovery score for the postanesthesia care unit
Corresponding Author:	Marlene Fischer, M.D., Ph.D. University Medical Center Hamburg-Eppendorf: Universitätsklinikum Hamburg-Eppendorf Hamburg, GERMANY
Keywords:	Quality of recovery; postanesthesia care unit; patient-reported outcome; recovery from anesthesia; perioperative care
Abstract:	<p>Introduction</p> <p>Patients' perception of postoperative recovery is a key aspect of perioperative care. Self-reported quality of recovery (QoR) has evolved as a relevant endpoint in perioperative research. Several psychometric instruments have been introduced to assess self-reported recovery 24 hours after surgery. However, there is no questionnaire suitable for use in the postanesthesia care unit (PACU). We aimed to develop and psychometrically evaluate a QoR questionnaire for the PACU (QoR-PACU).</p> <p>Methods</p> <p>The QoR-PACU was developed based on the 40-item QoR-40 questionnaire. Adult patients scheduled for elective urologic surgery completed the QoR-PACU preoperatively and during the PACU stay. We evaluated feasibility, validity, reliability, and responsiveness. Between March and November 2020 we enrolled 375 patients. After a pretest phase the questionnaire was modified twice to ensure ease of understanding.</p> <p>Results</p> <p>We administered the final version of the QoR-PACU to 255 patients, with a completion rate of 96.5%. Construct validity was good with postoperative QoR-PACU sum scores correlating with age ($r = 0.23$, 95%CI: 0.11 to 0.35, $p < 0.001$), length of PACU stay ($r = -0.15$, 95%CI: -0.27 to -0.03, $p = 0.02$), pain in the PACU ($r = -0.48$, 95%CI: -0.57 to -0.37, $p < 0.001$) and piritramide dose administered ($r = -0.29$, 95%CI: -0.40 to -0.17, $p < 0.001$). Cronbach's alpha was 0.67 (95%CI: 0.61 – 0.73) with moderate test-retest reliability (ICC of 0.67, 95%CI: 0.38 – 0.83). Cohen's effect size was 3.08 and the standardized response mean was 1.65 indicating adequate responsiveness.</p> <p>Conclusion</p> <p>The assessment of QoR in the early postoperative period is feasible. We found high acceptability with excellent recruitment and successful completion rates, adequate responsiveness, and sufficient validity and reliability. Future studies should evaluate the psychometric properties of the QoR-PACU in more heterogeneous patient populations including female and gender-diverse patients with varying degrees of perioperative risk.</p>
Order of Authors:	Ursula Kahl, M.D. Katrin Brodersen, M.D. Sarah Kaiser

	Linda Krause, M.Sc.
	Regine Klinger, PhD
	Lili Plümer, M.D.
	Christian Zöllner, M.D.
	Marlene Fischer, M.D., PhD
Additional Information:	
Question	Response
<p>Financial Disclosure</p> <p>Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS ONE for specific examples.</p> <p>This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.</p> <p>Unfunded studies Enter: <i>The author(s) received no specific funding for this work.</i></p> <p>Funded studies Enter a statement with the following details:</p> <ul style="list-style-type: none"> • Initials of the authors who received each award • Grant numbers awarded to each author • The full name of each funder • URL of each funder website • Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript? • NO - Include this sentence at the end of your statement: <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> • YES - Specify the role(s) played. <p>* typeset</p>	<p>Ursula Kahl was funded by the Clinician Scientist Program of the medical faculty of the University of Hamburg, during the conduct of the study. The University of Hamburg was not involved in any of the following: study design, conduct of the research, preparation of this manuscript, analysis and interpretation of data; writing of the report; decision to submit the article for publication.</p>
<p>Competing Interests</p> <p>Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors,</p>	<p>The authors have declared that no competing interests exist.</p>

disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement is **required** for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

View published research articles from [PLOS ONE](#) for specific examples.

NO authors have competing interests

Enter: *The authors have declared that no competing interests exist.*

Authors with competing interests

Enter competing interest details beginning with this statement:

I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]

* typeset

Ethics Statement

Enter an ethics statement for this submission. This statement is required if the study involved:

- Human participants
- Human specimens or tissue
- Vertebrate animals or cephalopods
- Vertebrate embryos or tissues
- Field research

Write "N/A" if the submission does not require an ethics statement.

Ethical approval was obtained from the ethics committee at the Hamburg State Chamber of Physicians on February 11, 2020 (serial number PV7218). Each patient gave written informed consent before the initiation of study-related procedures.

General guidance is provided below. Consult the [submission guidelines](#) for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**

Format for specific study types

Human Subject Research (involving human participants and/or tissue)

- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

Animal Research (involving vertebrate animals, embryos or tissues)

- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

Field Research

Include the following details if this study involves the collection of plant, animal, or other materials from a natural setting:

- Field permit number
- Name of the institution or relevant body that granted permission

Data Availability

Authors are required to make all data

No - some restrictions will apply

underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

Important: Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following: *All relevant data are within the manuscript and its Supporting Information files.*
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

Data cannot be shared publicly because of [XXX]. Data are available from the

Data cannot be shared publicly because of the German General Data Protection Regulation. Data are available from the corresponding author Marlene Fischer (contact via mar.fischer@uke.de) for researchers who meet the criteria for access to confidential data.

XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party and contact information or URL).

- This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.

* typeset

Additional data availability information:



1 **Title**

2 Psychometric evaluation of a quality of recovery score for the postanesthesia care unit – a
3 prospective validation study

4

5 **Authors**

6 Ursula Kahl¹, Katrin Brodersen¹, Sarah Kaiser¹, Linda Krause², Regine Klinger¹, Lili Plümer¹,
7 Christian Zöllner¹, Marlene Fischer^{1,3}

8

9 **Affiliations**

10 ¹Department of Anesthesiology, University Medical Center Hamburg-Eppendorf, Hamburg,
11 Germany;

12 ²Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf,
13 Hamburg, Germany;

14 ³Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf,
15 Hamburg, Germany.

16

17 ***Corresponding author**

18 Marlene Fischer, MD, Ph

19 Department of Anaesthesiology,

20 University Medical Center Hamburg-Eppendorf

21 Martinistrasse 52

22 20246 Hamburg, Germany

23 Phone: +4915222827500

24 Email: mar.fischer@uke.de

25

26 **Details of authors' contributions**

27 UK acquisition, analysis and interpretation of data, drafting the article

28 KB acquisition, analysis and interpretation of data, drafting the article

29 SK acquisition, substantial revision of the manuscript

30 LK analysis and interpretation of data, substantial revision of the manuscript

31 RK interpretation of data, substantial revision of the manuscript

32 CZ conception and design of the work, substantial revision of the manuscript

33 MF conception and design of the work, acquisition, analysis and interpretation of
34 data, drafting the article

35

36 **Abstract (max. 300 words)**

37
38 *Introduction:* Patients' perception of postoperative recovery is a key aspect of perioperative care.
39 Self-reported quality of recovery (QoR) has evolved as a relevant endpoint in perioperative
40 research. Several psychometric instruments have been introduced to assess self-reported
41 recovery 24 hours after surgery. However, there is no questionnaire suitable for use in the
42 postanesthesia care unit (PACU). We aimed to develop and psychometrically evaluate a QoR
43 questionnaire for the PACU (QoR-PACU).

44
45 *Methods:* The QoR-PACU was developed based on the 40-item QoR-40 questionnaire. Adult
46 patients scheduled for elective urologic surgery completed the QoR-PACU preoperatively and
47 during the PACU stay. We evaluated feasibility, validity, reliability, and responsiveness. Between
48 March and November 2020 we enrolled 375 patients. After a pretest phase the questionnaire was
49 modified twice to ensure ease of understanding.

50
51 *Results:* We administered the final version of the QoR-PACU to 255 patients, with a completion
52 rate of 96.5%. Construct validity was good with postoperative QoR-PACU sum scores correlating
53 with age ($r= 0.23$, 95%CI: 0.11 to 0.35, $p < 0.001$), length of PACU stay ($r= -0.15$, 95%CI: -0.27 to
54 -0.03, $p= 0.02$), pain in the PACU ($r= -0.48$, 95%CI: -0.57 to -0.37, $p < 0.001$) and piritramide dose
55 administered ($r= -0.29$, 95%CI: -0.40 to -0.17, $p < 0.001$). Cronbach's alpha was 0.67 (95%CI: 0.61
56 – 0.73) with moderate test-retest reliability (ICC of 0.67, 95%CI: 0.38 – 0.83). Cohen's effect size
57 was 3.08 and the standardized response mean was 1.65 indicating adequate responsiveness.

58
59 *Conclusion:* The assessment of QoR in the early postoperative period is feasible. We found high
60 acceptability with excellent recruitment and successful completion rates, adequate
61 responsiveness, and sufficient validity and reliability. Future studies should evaluate the

62 psychometric properties of the QoR-PACU in more heterogeneous patient populations including
63 female and gender-diverse patients with varying degrees of perioperative risk.

64

65

66 **Key words**

67 Quality of recovery, postanesthesia care unit, patient-reported outcome, recovery from
68 anesthesia, perioperative care.

69 **Introduction**

70 The improvement of postoperative recovery is a common aim of all disciplines involved in
71 perioperative care (1–3). Postoperative recovery after surgery and anesthesia has traditionally
72 been assessed using objective parameters including but not limited to cardiovascular, pulmonary
73 or infectious complications, pain or length of hospital stay (4–6). In recent years patient’s
74 perception of recovery after surgery has been increasingly recognized as a relevant outcome
75 measure (1,2,7). To allow for comparability across clinical studies, the *Standardized Endpoints in*
76 *Perioperative Medicine (StEP)* initiative recommends six standardized outcome measures
77 reflecting patient comfort: postoperative pain, nausea, time to gastrointestinal recovery, time to
78 mobilization, sleep disturbance, and the assessment of postoperative quality of recovery (QoR)
79 (8,9). In the same line, the introduction of patient-reported outcome assessments is recommended
80 by the *American Society for Enhanced Recovery and Perioperative Quality Initiative* (10). Various
81 instruments have been developed to evaluate postoperative patient-reported recovery. Myles and
82 colleagues developed the 40-item QoR-40 questionnaire that has been validated, translated, and
83 used extensively (2,11–14). In 2013, the same research group developed the 15-item QoR-15
84 questionnaire which is a shorter version of the more extensive QoR-40 (7,15–24). Both
85 instruments have been introduced to assess QoR one day after surgery (2,7). The importance of
86 advanced recovery room care and the assessment of patient-centered outcomes early after
87 surgery has recently been highlighted by an Australian feasibility study (25). Yet, there is no
88 instrument appropriate for application in the postanesthesia care unit (PACU).

89 The aim of this study was to develop a QoR questionnaire for the PACU (QoR-PACU) and to
90 evaluate its feasibility, validity, reliability, responsiveness, and clinical acceptability in patients after
91 general anesthesia for elective non-cardiac surgery.

92 **Materials and Methods**

93 *Ethical approval and study registration*

94 Ethical approval was obtained from the ethics committee at the Hamburg State Chamber of
95 Physicians on February 11, 2020 (serial number PV7218). Each patient gave written informed
96 consent before the initiation of study-related procedures. The study was registered at
97 clinicaltrials.gov (NCT04528537).

98

99 *Study design and participants*

100 We performed a prospective observational cohort study at the Department of Anesthesiology of a
101 quaternary care university hospital in Northern Germany. We performed a pre-test of the QoR-
102 PACU in a randomly selected cohort of 10 patients to assess feasibility. Subsequently, all study
103 participants completed the QoR-PACU on the day before surgery to obtain baseline values.
104 Patients were assessed postoperatively 120 minutes after arrival in the PACU allowing for a
105 tolerance interval of ± 60 minutes. A subgroup of patients underwent a second postoperative
106 assessment after another 60 minutes ± 30 to evaluate test-rest reliability. Additionally, test-retest
107 reliability was assessed in a subset of patients on the first postoperative day. All assessments
108 were performed by three examiners (KB, SK, MF).

109 Patients were included, if they were 18 years or older and received general anesthesia for elective
110 radical prostatectomy. We excluded patients scheduled for Same-Day-Surgery, ambulatory
111 surgery or postoperative admission to the intensive care unit and patients without excellent
112 German language skills.

113

114 *Development and adaptation of the QoR-PACU*

115 With the permission of Professor Paul Myles, we aimed to develop a questionnaire derived from
116 the QoR-40 to assess the QoR in PACU. Three experienced anesthesiologists (MF, LN, CZ)
117 independently selected 15 items each from the QoR-40, which they deemed to be of high clinical

118 importance for recovery and self-perceived health status during the early postoperative period.
119 After thorough discussion a consensus version containing 16 items was developed (version 1).
120 Similar to the QoR-15 questionnaire, an 11-point numerical rating scale was used with a score
121 from 0 (“none of the time”) to 10 (“all of the time”). For negative items the scoring was reversed. A
122 total score was calculated ranging from 0 to 160 points, with a higher score representing better
123 recovery. After a successful pretest phase, we administered the 16-item QoR-PACU (version 1)
124 to 72 patients. During the early study period we repeatedly noticed misunderstandings. One major
125 issue was the 11-point response scale from 0 to 10, reflecting the frequency of positive or negative
126 symptoms. A relevant number of patients was confused with simultaneous pain ratings, which are
127 part of clinical practice in the PACU, and assessed intensity rather than frequency. Therefore, we
128 reduced the 11-point scale to a 5-point scale from 0 to 4 (version 2). For ease of understanding
129 we linked each number with an adverb of frequency: 4 points = always, 3 points = most of the
130 time, 2 points = occasionally, 1 point = rarely, 0 points = never, resulting in a total score from 0 to
131 52 points. For negative items the scoring was reversed. After assessment of another 48 patients,
132 the QoR-PACU questionnaire was reduced to 13 items (version 3, S1 Table, S2 Table). Four items
133 were dropped for lack of importance as reported by patients and PACU staff: the distinction
134 between severe and moderate pain, shivering, bad dreams and the feeling of being alone. The
135 item “nausea and vomiting” was separated into two items.

136

137 *Data collection*

138 Medical history and demographic characteristics were collected during the preanesthesia visit. We
139 recorded the following clinical data: age, gender, body mass index, Charlson Comorbidity Index
140 (CCI), obstructive sleep apnea syndrome, medication, American Society of Anesthesiologists
141 (ASA) physical status classification, education, and current profession. To preoperatively assess
142 the risk for obstructive sleep apnea syndrome we used the STOP-Bang score that evaluates
143 snoring, tiredness, observed apnea, high blood pressure, body mass index, age, neck

144 circumference, and male gender with higher scores indicating a higher risk. We retrieved
145 information about the duration of surgery, length of PACU stay, intra- and perioperative medication
146 from anesthesia protocols. The Numeric Rating Scale (NRS) was used to assess pain intensity in
147 the PACU.

148

149 *Sample Size*

150 There is no consistent recommendation regarding sample size for the development and the
151 evaluation of a questionnaire. A “rule of thumb” suggests at least 10 participants for each scale
152 item (26,27). Others propose a sample size 300 after initial pretesting (28). To meet both criteria
153 we opted for 375 patients including an estimated drop-out rate of 25%.

154

155 *Statistical analysis*

156 Continuous variables are presented as median with 25th and 75th percentiles. Categorical variables
157 are given as absolute and relative numbers.

158 Validity was assessed using the postoperative QoR-PACU sum score. To assess construct validity
159 we compared postoperative QoR-PACU sum scores between categories of clinically relevant
160 variables using a linear model and analysis of variance. Additionally, we analyzed correlations
161 between postoperative QoR-PACU sum scores and clinically relevant continuous variables using
162 Pearson’s product-moment correlation coefficients and corresponding 95% confidence intervals.

163 Reliability was analyzed using results of individual items of the postoperative QoR-PACU and sum
164 scores of postoperative QoR-PACU of those who took the tests twice postoperatively. Reliability
165 was assessed based on internal consistency using Cronbach’s alpha, split-half reliability and test-
166 retest reliability using Pearson’s correlation coefficient. Pearson correlation was chosen over the
167 intraclass correlation coefficient since it is reasonable to assume that the state of the patient
168 changed within the one hour of time between both assessments (29).

169 Cronbach's alpha was calculated between items of the postoperative QoR-PACU using the alpha
170 function from the R-package "psych" version 2.1.9 (30). An alpha coefficient of 0.70 and higher is
171 considered to be an acceptable threshold for reliability (26). To obtain split-half reliability the
172 function splithalf.r from the "multicon" R-package in the version 1.6 was used on the items of the
173 postoperative QoR-PACU results (31).

174 Responsiveness refers to the ability to detect clinical important change. Responsiveness was
175 analyzed taking into account pre- and postoperative QoR-PACU sum scores and was expressed
176 with Cohen's effect size and standardized response mean. Cohen's effect size is defined as mean
177 difference between preoperative and postoperative QoR-PACU sum scores divided by the SD of
178 the preoperative QoR-PACU sum scores. Standardized response mean was calculated as the
179 mean difference between pre- and postoperative QoR-PACU sum scores divided by the SD of
180 these differences.

181 The proportion of patients who successfully completed the QoR-PACU postoperatively was used
182 to assess acceptability and feasibility.

183 All analyses were done on complete available cases so no imputation of missing data was
184 performed. P-values are presented as descriptive summary measures and do not represent
185 results of confirmatory testing. No adjustment for multiplicity was performed. All analyses were
186 performed with R Statistical Software, version 3.5.3 (R Foundation for Statistical Computing,
187 Vienna, Austria).

188 **Results**

189 *Demographic and clinical characteristics*

190 Between March and November 2020, 246 patients were approached by the study team for the
191 assessment with version 3. A total of 246 patients completed the final version of the QoR-PACU
192 questionnaire resulting in a completion rate of 96.5%. Figure 1 shows the flow of participants
193 during the course of the study. Details on baseline demographic and clinical characteristics and
194 perioperative variables related to surgery and anesthesia are presented in Table 1.

195

196 **Figure 1: Flow chart**

197 Fig. 1: The flow diagram shows patients included and excluded throughout the course of the study.

198

199 **Table 1 : Demographic and clinical characteristics**

		n = 246
Patient characteristics		
Age (years)		64 (60; 69)
Body Mass Index (kg/m ²)		26.5 (24.5; 28.9)
ASA physical status		
	<i>II</i>	214 (87)
	<i>III</i>	32 (13)
Charlson Comorbidity Index		4 (4; 5)
Obstructive sleep apnea syndrome		17 (7.6)
Education		
	<i><9 years</i>	2 (0.8)
	<i>9 - 10 years</i>	28 (11.4)
	<i>10 - 12 years</i>	95 (38.6)
	<i>12 - 13 years</i>	16 (6.5)
	<i>University degree</i>	105 (42.7)
Surgery		
Duration of surgery (min)		153.0 (135.0; 175.8)
Surgical approach		
	<i>Open retropubic radical prostatectomy</i>	104 (42.3)
	<i>Robot-assisted radical prostatectomy</i>	142 (57.7)

Anaesthesia and perioperative medication

Duration of anaesthesia (min)	223.5 (206.0; 247.8)
Premedication with Midazolam	8 (3.3)
Prophylaxis for postoperative nausea and vomiting	
<i>None</i>	2 (0.8)
<i>Dexamethasone</i>	6 (2.4)
<i>Ondansetron</i>	3 (1.2)
Dexamethasone and Ondansetron	235 (95.5)
Anaesthesia maintenance	
<i>Sevoflurane</i>	241 (98.0)
<i>Propofol</i>	5 (2.0)
Sufentanil (cumulative; µg)	85.0 (70.0; 95.0)
Norepinephrine (maximum dosage; µg/kg/min)	0.1 (0.07; 0.14)
Fluids	
<i>Crystalloids (ml)</i>	2500 (2000; 3000)
<i>Colloids (ml)</i>	0 (0;0)

Postoperative care and medication

Length of PACU stay (min)	152.0 (118.3;196.5)
Piritramide (cumulative; mg)	3.75 (3.75;7.5)
Pethidine (cumulative; mg)	25.0 (25.0;25.0)
Discharge to	
<i>Normal ward</i>	208 (84.6)
<i>Scheduled overnight PACU stay</i>	27 (11.0)
<i>Unscheduled overnight PACU stay</i>	11 (4.5)

Table 1: Demographic and clinical characteristics. Data are presented as median (25th; 75th percentile) or n (%). ASA: American Society of Anesthesiologists. PACU: postanesthesia care unit.

201 QoR-PACU

202 Median QoR-PACU sum scores were 50.0 [IQR 48.0; 51.0] points (preoperative assessment),
 203 42.0 [IQR 38.0; 44.0] points (1st PACU assessment), 45.0 [IQR 42.5;47.0] points (2nd PACU
 204 assessment), and 45.0 [IQR 42.8;47.3] points (24 h assessment). Patients completed the
 205 questionnaires at a median time of 125.0 min [IQR 83.0; 156.8] after arrival in the PACU. The
 206 subgroup of patients, who underwent a second assessment in the PACU, completed the
 207 questionnaires at a median time of 189.0 min [IQR 148.8; 215.8]. Pre- and postoperative mean
 208 QoR-PACU scores for each item and the mean sum score are presented in Table 2. Figure 2
 209 shows pre- and postoperative QoR-PACU scores.

210

211 **Table 2 : Responsiveness**

212
 213

QoR-PACU item	Preoperative	Postoperative	Mean change [95% CI]	% change from baseline	Cohen effect size	Standardised response mean
1	3.7 ± 0.6	2.1 ± 1.2	-1.6 [-1.8; -1.5]	43.0	2.6	1.2
2	3.8 ± 0.5	2.3 ± 1.2	-1.6 [-1.7; -1.4]	39.0	3.2	1.2
3	3.7 ± 0.6	1.7 ± 1.1	-2.1 [-2.2; -1.9]	54.0	3.4	1.7
4	3.9 ± 0.4	3.6 ± 0.7	-0.3 [-0.4; -0.2]	7.7	0.7	0.4
5	4.0 ± 0.2	3.6 ± 0.8	-0.3 [-0.4; -0.3]	10.0	1.9	0.5
6	4.0 ± 0.1	4.0 ± 0.2	0.0 [-0.1; 0.0]	0.0	0.0	0.0
7	3.9 ± 0.4	3.7 ± 0.7	-0.2 [-0.3; -0.1]	5.1	0.5	0.3
8	4.0 ± 0.2	2.4 ± 1.2	-1.6 [-1.7; -1.4]	40.0	9.6	1.4
9	4.0 ± 0.2	3.5 ± 0.9	-0.5 [-0.6; -0.4]	12.0	2.2	0.6
10	3.4 ± 0.9	3.7 ± 0.6	0.3 [0.2; 0.5]	-8.8	-0.4	-0.3
11	3.7 ± 0.5	3.7 ± 0.6	-0.1 [-0.1; 0.0]	0.0	0.0	0.0
12	3.4 ± 0.6	3.2 ± 0.8	-0.2 [-0.3; -0.1]	5.9	0.3	0.2
13	3.8 ± 0.4	3.9 ± 0.4	0.0 [0.0; 0.1]	-2.6	-0.2	-0.2
Sum	49.0 ± 2.6	41.0 ± 5.0	-8.0 [-8.6; -7.4]	16.0	3.1	1.7

Table 2: Mean QoR-PACU scores for each item and the mean QoR-PACU sum score. Responsiveness is expressed with Cohen effect size (difference between preoperative and postoperative QoR-PACU scores, divided by the preoperative SD) and the standardized response mean (score difference divided by the SD of the score difference). Numbers are given as mean ± standard deviation (SD) unless otherwise indicated. QoR: Quality of recovery, PACU: postanesthesia care unit; CI: confidence interval.

214

215 **Fig. 2: Responsiveness**

216 Fig. 2. The radar chart – spider diagram shows mean scores of single items of the QoR-PACU
 217 preoperatively (green), in the PACU (red), at re-assessment in the PACU (purple), and on the day
 218 after surgery (pink). Each item of the questionnaire is presented as a spoke. The 5-point numeric
 219 rating scale is presented on the axis with numbers from 0 to 4.

220
 221 *Validity, reliability, and responsiveness*
 222 The comparison of postoperative QoR-PACU sum scores across categories of clinically relevant
 223 variables is presented in Table 3. The correlation between postoperative QoR-PACU sum scores
 224 and clinically relevant continuous variables is presented in Figure 3. Cronbach's alpha was 0.67
 225 (95% CI: 0.61 to 0.73), reflecting moderate internal consistency (32). The average of all split-half
 226 correlations was 0.52. The average of all split-half reliabilities was 0.69 ± 0.08 . Interitem
 227 correlations and correlations between the QoR-PACU sum score and each item are presented in
 228 Figure 4 and S3 Table. There was a positive correlation between QoR-PACU score and the score
 229 at the second assessment approximately one hour later ($r = 0.71$, 95%CI: 0.37 to 0.88, $p < 0.01$)
 230 reflecting acceptable test-retest reliability. Cohen's effect size and standardized response mean
 231 are presented in Table 2.

232
 233 **Table 3 : Construct validity**
 234

Variables	Postoperative QoR-PACU score	P
ASA physical status		0.867
	<i>II (n=214)</i>	42 [38;45]
	<i>III (n=32)</i>	43 [40;44]
OSAS^a		0.134
	<i>Low or intermediate risk (n=133)</i>	41 [38;44]
	<i>High risk or confirmed disease (n=91)</i>	42 [40;45]
Premedication with midazolam		0.247
	<i>no (n=238)</i>	42 [38;44]

	<i>yes (n=8)</i>	44 [43;45]	
Mode of intubation			0.257
	<i>Direct laryngoscopy (n=225)</i>	42 [38;44]	
	<i>Video-assisted laryngoscopy (n=3)</i>	46 [42;48]	
	<i>Switch from direct to video-assisted laryngoscopy (n=18)</i>	42 [37;42]	
Sevoflurane			0.539
	<i>no (n=5)</i>	39 [38;42]	
	<i>yes (n=241)</i>	42 [38;44]	
Propofol			0.539
	<i>no (n=241)</i>	42 [38;44]	
	<i>yes (n=5)</i>	39 [38;42]	
Depth of anaesthesia monitoring			0.650
	<i>no (n=3)</i>	42 [42;43]	
	<i>yes (n=243)</i>	42 [38;45]	
Antiemetic prophylaxis			0.761
	<i>none (n=2)</i>	39 [38;41]	
	<i>dexamethasone (n=6)</i>	40 [37;44]	
	<i>ondansetron (n=3)</i>	43 [38;46]	
	<i>dexamethasone + ondansetron (n=235)</i>	42 [39;45]	

Table 3: Construct validity of categorical variables. Data are presented as median [25th; 75th percentile]. ASA: American Society of Anesthesiologists. OSAS: obstructive sleep apnea syndrome.

235

236 Fig 3: Construct validity

237 Fig 3. Correlation between postoperative QoR-PACU sum scores and clinically relevant
238 continuous variables.

239

240 Fig 4: Inter-item correlation

241 Fig. 4. Correlation between each item and between the sum score and each item of the
242 postoperative QoR-PACU using Spearman correlation coefficient.

243 **Discussion**

244 The aim of this study was to establish a questionnaire to assess self-reported QoR during the
245 recovery period after elective non-cardiac surgery. We developed the QoR-PACU based on the
246 40-item QoR-40 questionnaire. We found high acceptability and feasibility with excellent
247 recruitment and successful completion rates, good validity, adequate responsiveness, and
248 moderate reliability.

249
250 A standardized tool for the assessment of patient reported QoR in the PACU is urgently needed
251 for both research and clinical purposes. Myles et al emphasize that results of clinical research can
252 only be considered valid if a reconfirmation is possible (8). However, comparability and impact of
253 clinical research is substantially diminished by different outcome definitions and the use of
254 numerous instruments for psychometric assessment (8,9,33). Therefore, it is important to
255 standardize the endpoints in clinical research.

256 For decades the Aldrete scoring system has been widely used to determine, if a patient can be
257 safely discharged from the PACU (20). Items addressed by the Aldrete score are limited to
258 physical aspects: activity, respiration, circulation, consciousness and color / oxygen saturation
259 (21,34). However, the definition of adequate recovery may differ substantially between patients
260 and caregivers. Including the patients' perception of postoperative recovery immediately after
261 surgery provides a basis for the optimization of recovery, which may result in better outcomes and
262 might even have a beneficial effect on length of stay and healthcare costs (3).

263
264 We chose clinically relevant aspects of intra- and postoperative care to assess construct validity.
265 Pain intensity, piritramide dose, and PACU length of stay negatively correlated with QoR in the
266 PACU. Our results confirm that pain perception plays a substantial role in perioperative care with
267 a major impact on patient's perception of health status and recovery (35). Despite homogeneity of
268 surgical procedures we found a large range of PACU length of stay. Shorter stay in the PACU

269 correlated with better QoR, which confirms previous reports on the association between PACU
270 length of stay and postoperative complications (36).

271 Psychometric properties of the QoR-PACU revealed good validity and adequate responsiveness
272 however, measures of reliability including internal consistency were moderate. The fact that the
273 internal consistency of the QoR-PACU was not as high as expected is interesting, since all items
274 of the QoR-PACU were derived from the QoR-40 which has been developed to evaluate the
275 quality of recovery 24 hours after surgery and has been validated extensively. Items showing high
276 validity and reliability 24 hours after surgery showed only sufficient internal consistency in the
277 immediate postoperative period. Several factors may account for the difference in internal
278 consistency. First and most importantly, the patients' mental and physical condition changes
279 rapidly during the early postoperative period. Of note, vigilance and pain perception are
280 interconnected. When the effects of anesthesia and analgesia wear off, consciousness improves
281 and patients become more susceptible to postoperative pain. Therefore, it is reasonable to expect
282 that self-perceived recovery in the early postoperative period will change substantially within a 30-
283 minute time frame. Second, we noticed that the simultaneous application of measures of
284 frequency, as used in the QoR-PACU, and measures of intensity, as used in the NRS, during the
285 recovery period led to confusion with study participants. We tried to avoid this problem by reducing
286 the 11-point scale to a 5-point scale linked with adverbs of frequency. Yet, difficulty in
287 understanding measures of frequency might have influenced our results. Third, it is noteworthy
288 that we observed a relatively small change from preoperative to PACU scores in our study
289 population. The mean change from preoperative to PACU scores was <0.5 for 9 items, but not for
290 the features pain, feeling confused, dry mouth, and sore throat. The majority of patients had a
291 rather low perioperative risk as reflected by the ASA physical status. High perioperative risk has
292 been found to be associated with poor recovery after colorectal cancer surgery (37). Similarly, low
293 ASA physical status might have contributed to the overall high QoR reported by participants of our
294 study.

295
296 We found the application of the QoR-PACU during the recovery period feasible with high response
297 and completion rates. Sum scores were highest at baseline on the day before surgery and lowest
298 during assessment in the PACU followed by an increase on the first postoperative day. The
299 development of QoR-PACU sum scores over time indicates that the QoR-PACU adequately
300 mirrors QoR despite moderate internal consistency.

301
302 This validation study was performed at the PACU of a prostate cancer clinic. All surgical
303 procedures and perioperative care at our prostate cancer center are highly standardized. Although
304 allowing for excellent comparability between participants, generalizability is limited. We included
305 solely male patients scheduled for radical prostatectomy. Results from previous studies suggest
306 that gender aspects have an impact on postoperative QoR and speed of recovery. Overall, female
307 patients tend to have lower QoR and longer PACU stay (2,38,39). Moreover, pain intensity,
308 nausea, and vomiting after surgery are more frequently reported by female patients (38,40).
309 Gender aspects may be of high importance in individualized perioperative care and postoperative
310 recovery.

311
312 Future studies should evaluate the psychometric properties of the QoR-PACU in a more
313 heterogenous patient population, including female and gender diverse patients, as well as a
314 greater variety of patient-related and procedure-related risk factors. This might reveal, whether
315 the issue of moderate internal consistency was primarily linked to the characteristics of the initial
316 study cohort, or whether items have to be revised substantially to be suitable for patients in the
317 PACU. For the modification of the QoR-PACU, it might be helpful to consider suggestions from
318 patients and caregivers.

319

320 **Conclusion**

321 This study presents the development of a questionnaire to assess self-reported QoR after surgery
322 in the PACU. We found excellent feasibility, good validity and adequate responsiveness. Against
323 our hypothesis, we did not find a high internal consistency of the QoR-PACU. In future studies,
324 the QoR-PACU should be evaluated in more heterogeneous patient populations including female
325 and gender-diverse patients with varying degrees of perioperative risk.

326

327

328

329 **Acknowledgements**

330 The authors thank Lars Nawrath for his support in the process of selecting items of the QoR-40
331 questionnaire to develop the first version of the QoR-PACU.

332

333

334 All authors approved of the version to be published and agree to be accountable for all aspects of
335 the work, thereby ensuring that questions related to the accuracy or integrity of any part of the
336 work are appropriately investigated and resolved.

337

338 **References**

339

- 340 1. Myles PS, Hunt JO, Nightingale CE, Fletcher H, Beh T, Tanil D, et al. Development and
341 psychometric testing of a quality of recovery score after general anesthesia and surgery in
342 adults. *Anesth Analg*. 1999 Jan;88(1):83–90.
- 343 2. Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a
344 postoperative quality of recovery score: the QoR-40. *Br J Anaesth*. 2000 Jan;84(1):11–5.
- 345 3. Borrell-Vega J, Humeidan ML, Bergese SD. Defining quality of recovery - What is
346 important to patients? *Best Pract Res Clin Anaesthesiol*. 2018 Dec;32(3–4):259–68.
- 347 4. Myles PS. More than just morbidity and mortality - quality of recovery and long-term
348 functional recovery after surgery. *Anaesthesia*. 2020 Jan;75 Suppl 1:e143–50.
- 349 5. Shulman M, Myles P. Measuring perioperative outcome. *Curr Opin Anaesthesiol*. 2016
350 Dec;29(6):733–8.
- 351 6. Neville A, Lee L, Antonescu I, Mayo NE, Vassiliou MC, Fried GM, et al. Systematic
352 review of outcomes used to evaluate enhanced recovery after surgery. *Br J Surg*. 2014
353 Feb;101(3):159–70.
- 354 7. Stark PA, Myles PS, Burke JA. Development and psychometric evaluation of a
355 postoperative quality of recovery score: the QoR-15. *Anesthesiology*. 2013 Jun;118(6):1332–40.
- 356 8. Myles PS, Grocott MPW, Boney O, Moonesinghe SR, COMPAC-StEP Group.
357 Standardizing end points in perioperative trials: towards a core and extended outcome set. *Br J*
358 *Anaesth*. 2016 May;116(5):586–9.
- 359 9. Myles PS, Boney O, Botti M, Cyna AM, Gan TJ, Jensen MP, et al. Systematic review and
360 consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative:
361 patient comfort. *Br J Anaesth*. 2018 Apr;120(4):705–11.
- 362 10. Abola RE, Bennett-Guerrero E, Kent ML, Feldman LS, Fiore JF, Shaw AD, et al.
363 American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus
364 Statement on Patient-Reported Outcomes in an Enhanced Recovery Pathway. *Anesth Analg*.
365 2018 Jun;126(6):1874–82.
- 366 11. Vignaud M, Morel C, Henault A, Futier E, Pereira B, Lambert C, et al. Variability and
367 reliability of the French version of the Quality of Recovery-40 Questionnaire (QoR-40). *Anaesth*
368 *Crit Care Pain Med*. 2021 Apr;40(2):100822.
- 369 12. Chen Y, Wang J, Liu S, Lai W, Liu J, Wang Z, et al. Development and Validation of the
370 Chinese Version of the Quality of Recovery-40 Questionnaire. *Ther Clin Risk Manag*.
371 2020;16:1165–73.
- 372 13. Lee JH, Kim D, Seo D, Son JS, Kim DC. Validity and reliability of the Korean version of
373 the Quality of Recovery-40 questionnaire. *Korean J Anesthesiol*. 2018 Dec;71(6):467–75.

- 374 14. Terkawi AS, Myles PS, Riad W, Nassar SN, Mahmoud M, AlKahtani GJ, et al.
375 Development and validation of Arabic version of the postoperative quality of recovery-40
376 questionnaire. *Saudi J Anaesth.* 2017 May;11(Suppl 1):S40–52.
- 377 15. Kleif J, Edwards HM, Sort R, Vilandt J, Gögenur I. Translation and validation of the
378 Danish version of the postoperative quality of recovery score QoR-15. *Acta Anaesthesiol Scand.*
379 2015 Aug;59(7):912–20.
- 380 16. Demumieux F, Ludes PO, Diemunsch P, Bennett-Guerrero E, Lujic M, Lefebvre F, et al.
381 Validation of the translated Quality of Recovery-15 questionnaire in a French-speaking
382 population. *Br J Anaesth.* 2020 Jun;124(6):761–7.
- 383 17. Kim D, Kim JK, Yeo J. Translation and Validation of the Korean Version of the
384 Postoperative Quality of Recovery Score QoR-15. *BioMed Res Int.* 2020;2020:3456234.
- 385 18. Kahl U, Gebhardt N, Brodersen K, Kainz E, Schirren L, Yu Y, et al. Validation of a
386 translated Quality of Recovery-15 questionnaire in German patients undergoing elective
387 noncardiac surgery. *Br J Anaesth.* 2021 Nov;127(5):e161–3.
- 388 19. Picconi E, Iacobucci T, Adducci E, Gualtieri E, Beccia G, Sollazzi L. Translation and
389 validation of the Italian version of the postoperative quality of recovery score QoR-15. *Minerva*
390 *Anesthesiol.* 2020 Jul;86(7):787–9.
- 391 20. Nakatani S, Ida M, Tanaka Y, Okamoto N, Wang X, Nakatani H, et al. Translation and
392 validation of the Japanese Version of the Quality of Recovery-15 Questionnaire. *J Anesth.* 2021
393 Jun;35(3):426–33.
- 394 21. Aldrete JA, Kroulik D. A postanesthetic recovery score. *Anesth Analg.* 1970
395 Dec;49(6):924–34.
- 396 22. Sá AC, Sousa G, Santos A, Santos C, Abelha FJ. Quality of Recovery after Anesthesia:
397 Validation of the Portuguese Version of the ‘Quality of Recovery 15’ Questionnaire. *Acta Med*
398 *Port.* 2015 Oct;28(5):567–74.
- 399 23. Miklič Bubić M, Miklič P, Barl P, Matas M, Sekulić A. CROATIAN VERSION OF THE
400 QUALITY OF RECOVERY QUESTIONNAIRE (QoR-40): TRANSCULTURAL ADAPTATION
401 AND VALIDATION. *Acta Clin Croat.* 2021 Jun;60(2):237–45.
- 402 24. Yaghoobi S, Hamidfar M, Lawson DM, Fridlund B, Myles PS, Pakpour AH. Validity and
403 reliability of the Iranian version of the quality of recovery-40 questionnaire. *Anesthesiol Pain*
404 *Med.* 2015 Apr;5(2):e20350.
- 405 25. Ludbrook G, Lloyd C, Story D, Maddern G, Riedel B, Richardson I, et al. The effect of
406 advanced recovery room care on postoperative outcomes in moderate-risk surgical patients: a
407 multicentre feasibility study. *Anaesthesia.* 2021 Apr;76(4):480–8.
- 408 26. Boateng GO, Neilands TB, Frongillo EA, Melgar-Quiñonez HR, Young SL. Best Practices
409 for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer.
410 *Front Public Health.* 2018;6:149.
- 411 27. Nunnally J. *Psychometric Theory.* 1978.

- 412 28. Clark LA, Watson D. Constructing validity: Basic issues in objective scale development.
413 Psychol Assess. 1995 Sep;7(3):309–19.
- 414 29. Vetter TR, Cubbin C. Psychometrics: Trust, but Verify. Anesth Analg. 2019
415 Jan;128(1):176–81.
- 416 30. Revelle W. psych: Procedures for Psychological, Psychometric, and Personality
417 Research [Internet]. 2021 [cited 2022 May 1]. Available from: [https://CRAN.R-](https://CRAN.R-project.org/package=psych)
418 [project.org/package=psych](https://CRAN.R-project.org/package=psych)
- 419 31. Sherman RA. multicon: Multivariate Constructs [Internet]. 2015 [cited 2022 May 1].
420 Available from: <https://CRAN.R-project.org/package=multicon>
- 421 32. Taherdoost H. Validity and Reliability of the Research Instrument; How to Test the
422 Validation of a Questionnaire/Survey in a Research. SSRN Electron J [Internet]. 2016 [cited
423 2022 Jun 20]; Available from: <https://www.ssrn.com/abstract=3205040>
- 424 33. Bowyer A, Royse C. The importance of postoperative quality of recovery: influences,
425 assessment, and clinical and prognostic implications. Can J Anaesth J Can Anesth. 2016
426 Feb;63(2):176–83.
- 427 34. Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth. 1995
428 Feb;7(1):89–91.
- 429 35. Nimmo SM, Foo ITH, Paterson HM. Enhanced recovery after surgery: Pain management.
430 J Surg Oncol. 2017 Oct;116(5):583–91.
- 431 36. Mann-Farrar J, Egan E, Higgins A, Wysocki L, Vaux A, Arndell E, et al. Are Postoperative
432 Clinical Outcomes Influenced by Length of Stay in the Postanesthesia Care Unit? J
433 Perianesthesia Nurs Off J Am Soc PeriAnesthesia Nurses. 2019 Apr;34(2):386–93.
- 434 37. Jakobsson J, Idvall E, Kumlien C. Patient characteristics and surgery-related factors
435 associated with patient-reported recovery at 1 and 6 months after colorectal cancer surgery. Eur
436 J Cancer Care (Engl). 2017 Nov;26(6).
- 437 38. Buchanan FF, Myles PS, Cicuttini F. Effect of patient sex on general anaesthesia and
438 recovery. Br J Anaesth. 2011 Jun;106(6):832–9.
- 439 39. Myles PS, McLeod AD, Hunt JO, Fletcher H. Sex differences in speed of emergence and
440 quality of recovery after anaesthesia: cohort study. BMJ. 2001 Mar 24;322(7288):710–1.
- 441 40. Buchanan FF, Myles PS, Cicuttini F. Patient sex and its influence on general
442 anaesthesia. Anaesth Intensive Care. 2009 Mar;37(2):207–18.
- 443

444 **Supporting information**

445

446 **S1 Table. QoR-PACU Version 3.0 preoperative.**

447

448 **S2 Table. QoR-PACU Version 3.0 postoperative.**

449

450 **S3 Table. Postoperative interitem correlation.**

451 S3 Table: Postoperative assessment: Interitem correlations for the 13 items of the QoR-PACU
452 score. Correlations are expressed as Pearson correlation coefficients.




Figure 2

[Click here to access/download;Figure;PACQOR 3 Figure 2 spider 2021-08-26.pdf](#)




Figure 3






Figure 4

[Click here to access/download;Figure;PACQ](#)





[Click here to access/download](#)

Supporting Information

[Supplementary_Table_1_070722.docx](#)






[Click here to access/download](#)

Supporting Information

[Supplementary_Table_2_070722.docx](#)





Click here to access/download
Supporting Information
S3_Table.docx